PREDILIFE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.9 EUR | -1.43% |
|
+9.52% | +21.05% |
| 2023 | Predilife: a project accredited by Finance Innovation | CF |
| 2023 | Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 3L 3L 2.61Cr | Sales 2023 * | - | Capitalization | 2.59Cr 2.8Cr 234.05Cr |
|---|---|---|---|---|---|
| Net income 2022 * | - | Net income 2023 * | - | EV / Sales 2022 | 79.4 x |
| Net cash position 2022 | 35.2L 38.09L 32Cr | Net cash position 2023 * | - 0 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 * |
-
| Employees | 20 |
| Yield 2022 * |
-
| Yield 2023 * |
-
| Free-Float | 92.59% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.43% | ||
| 1 week | +9.52% | ||
| Current month | +33.98% | ||
| 1 month | +53.33% | ||
| 3 months | +53.33% | ||
| 6 months | +22.12% | ||
| Current year | +21.05% |
1 week
6.70
7.45
1 month
4.0824.00
Current year
3.6024.00
1 year
3.6024.00
3 years
3.6024.00
5 years
3.6024.00
10 years
3.6024.00
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Ragusa
CEO | Chief Executive Officer | 53 | 01/04/01 |
Émilien Gauthier
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/01 |
Marion Renelier
LAW | General Counsel | - | 01/16/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Vilgrain
BRD | Director/Board Member | 44 | 01/18/01 |
Stéphane Ragusa
CEO | Chief Executive Officer | 53 | 01/04/01 |
Antoine Bricard
BRD | Director/Board Member | 56 | 01/18/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/24/14 | 6.9 | -1.43% | 1 697 |
| 13/24/13 | 7 | -0.71% | 1,457 |
| 10/24/10 | 7.05 | +4.44% | 5,105 |
| 09/24/09 | 6.75 | -1.46% | 2,034 |
| 08/24/08 | 6.85 | -8.67% | 9,603 |
Real-time Euronext Paris, May 14, 2024 at 08:11 pm IST
More quotes
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women,over 300,000 French women and 500,000 English.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +21.05% | 2.8Cr | |
| -27.01% | 1.03TCr | |
| +31.86% | 304.46Cr | |
| -8.58% | 293.69Cr | |
| -13.62% | 219.3Cr | |
| -16.32% | 172.01Cr | |
| +63.36% | 139.87Cr | |
| +27.00% | 78Cr | |
| -2.18% | 74Cr | |
| -19.18% | 56Cr |
- Stock Market
- Equities
- ALPRE Stock
